TYRX Reaches Major Implant Milestone

   TYRX, Inc. announced that it has successfully implanted its AIGISRx device in 10,000 patients in the United States. The AIGISRx device is an antibacterial mesh technology that securely holds a pacemaker (PM) or implantable cardioverter defibrillator (ICD) in place to create a stable environment, while delivering antimicrobial agents, rifampin and minocycline. These antimicrobial agents have been shown to reduce infections associated with medical devices in multiple randomized controlled trials.     “The number of patients with serious CIED-related infections in the U.S. continues to increase out of proportion to the increase in implantation rates. And with major infection rates of 3% to 4% being commonly seen, there is a need for a locally-delivered therapy to help prevent these infections. I began to utilize the antibacterial envelope in 2009 and have found it to be very effective for CIED infection prophylaxis,” remarked Peter Taylor, MD, MBA, FACC, attending physician, Orlando Health, Orlando, Florida.     “Reaching this 10,000th AIGISRx implant milestone is a remarkable achievement and a testament to our team who has worked tirelessly and enthusiastically to develop this important technology to address a significant clinical need,” said Robert White, TYRX President and CEO. “Approximately one out of 50 patients in the U.S. experiences a major infection problem at a cost of approximately $50,000 per patient. The AIGISRx Antibacterial Envelope provides hospitals and clinicians with a way to improve patient outcomes while reducing the corresponding economic burden.”